176 related articles for article (PubMed ID: 37421190)
21. Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL.
Nicholls D; Barrett R; Button P; Truman M; Bird P; Roberts L; Tymms K; Littlejohn G; Griffiths H
Intern Med J; 2018 Oct; 48(10):1185-1192. PubMed ID: 29968400
[TBL] [Abstract][Full Text] [Related]
22. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.
Wilke T; Mueller S; Lee SC; Majer I; Heisen M
BMC Musculoskelet Disord; 2017 Aug; 18(1):332. PubMed ID: 28764705
[TBL] [Abstract][Full Text] [Related]
23. Temporal Trends in Use of Biologic DMARDs for Rheumatoid Arthritis in the United States: A Cohort Study of Publicly and Privately Insured Patients.
Desai RJ; Solomon DH; Jin Y; Liu J; Kim SC
J Manag Care Spec Pharm; 2017 Aug; 23(8):809-814. PubMed ID: 28737992
[TBL] [Abstract][Full Text] [Related]
24. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan.
Tang CH; Yu F; Huang CY; Chen DY
Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863
[TBL] [Abstract][Full Text] [Related]
25. Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort study.
Ouardi NE; Maghraoui AE; Djossou HJ; Taoubane L; Ghassem AM; Toufik H; Majjad A; Sadni S; Mounach A; Hmamouchi I; Abouqal R; Bahiri R; Allali F; Bouchti IE; Ghozlani I; Hassikou H; Harzy T; Ichchou L; Mkinsi O; Niamane R; Bezza A
Rheumatol Int; 2023 Jan; 43(1):79-87. PubMed ID: 36334121
[TBL] [Abstract][Full Text] [Related]
26. Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry.
Yoshida K; Kishimoto M; Radner H; Matsui K; Okada M; Saeki Y; Solomon DH; Tohma S
Rheumatology (Oxford); 2016 Feb; 55(2):286-90. PubMed ID: 26350484
[TBL] [Abstract][Full Text] [Related]
27. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
[TBL] [Abstract][Full Text] [Related]
28. Relapse in rheumatoid arthritis patients undergoing dose reduction and withdrawal of biologics: are predictable factors more relevant than predictive parameters? An observational prospective real-life study.
Vittecoq O; Desouches S; Kozyreff M; Nicolau J; Pouplin S; Rottenberg P; Sens N; Lequerre T; Avenel G
BMJ Open; 2019 Dec; 9(12):e031467. PubMed ID: 31857303
[TBL] [Abstract][Full Text] [Related]
29. Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010.
Ichinose K; Shimizu T; Umeda M; Fukui S; Nishino A; Koga T; Kawashiri SY; Iwamoto N; Tamai M; Nakamura H; Sato S; Origuchi T; Kawakami A
J Immunol Res; 2018; 2018():6259010. PubMed ID: 30186881
[TBL] [Abstract][Full Text] [Related]
30. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
Jones G; Hall S; Bird P; Littlejohn G; Tymms K; Youssef P; Chung E; Barrett R; Button P
Int J Rheum Dis; 2018 Aug; 21(8):1581-1590. PubMed ID: 29205926
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study.
Jinno S; Onishi A; Dubreuil M; Akashi K; Hashimoto M; Yamamoto W; Murata K; Takeuchi T; Kotani T; Maeda Y; Ebina K; Son Y; Amuro H; Hara R; Katayama M; Saegusa J; Morinobu A
Rheumatol Int; 2020 Dec; 40(12):1987-1995. PubMed ID: 32728836
[TBL] [Abstract][Full Text] [Related]
33. Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study.
Dreyer L; Cordtz RL; Hansen IMJ; Kristensen LE; Hetland ML; Mellemkjaer L
Ann Rheum Dis; 2018 Apr; 77(4):510-514. PubMed ID: 29217620
[TBL] [Abstract][Full Text] [Related]
34. Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort.
Baganz L; Richter A; Kekow J; Bussmann A; Krause A; Stille C; Listing J; Zink A; Strangfeld A
Rheumatol Int; 2018 Apr; 38(4):579-587. PubMed ID: 29143933
[TBL] [Abstract][Full Text] [Related]
35. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Shiba H; Son Y; Amuro H; Onishi A; Akashi K; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Arthritis Res Ther; 2020 Jun; 22(1):142. PubMed ID: 32539813
[TBL] [Abstract][Full Text] [Related]
36. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Ishikawa Y; Hashimoto M; Ito H; Tanaka M; Yukawa N; Fujii T; Yamamoto W; Mimori T; Terao C
Semin Arthritis Rheum; 2019 Oct; 49(2):204-210. PubMed ID: 30803720
[TBL] [Abstract][Full Text] [Related]
37. Successful discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in real-world settings.
Ochiai M; Tanaka E; Sato E; Inoue E; Abe M; Saka K; Sugano E; Sugitani N; Higuchi Y; Yamaguchi R; Sugimoto N; Ikari K; Nakajima A; Yamanaka H; Harigai M
Mod Rheumatol; 2021 Jul; 31(4):790-795. PubMed ID: 33538611
[TBL] [Abstract][Full Text] [Related]
38. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.
Tanaka E; Inoue E; Yamaguchi R; Shimizu Y; Kobayashi A; Sugimoto N; Hoshi D; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2017 Mar; 27(2):227-236. PubMed ID: 27472516
[TBL] [Abstract][Full Text] [Related]
39. Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting.
Lau AN; Wong-Pack M; Rodjanapiches R; Ioannidis G; Wade S; Spangler L; Balasubramanian A; Pannacciulli N; Lin CJF; Roy-Gayos P; Bensen WG; Bensen R; Adachi JD
J Rheumatol; 2018 Feb; 45(2):170-176. PubMed ID: 29142041
[TBL] [Abstract][Full Text] [Related]
40. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
